Jennifer L Pearson1,2, Amanda L Johnson1, Sarah E Johnson3, Cassandra A Stanton4,5, Andrea C Villanti1,2, Raymond S Niaura1,2, Allison M Glasser1, Baoguang Wang3, David B Abrams1,2,5, K Michael Cummings6, Andrew Hyland7. 1. The Schroeder Institute for Tobacco Research and Policy Studies, Legacy, Washington, DC, USA. 2. Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 3. Office of Science, Center for Tobacco Products, Food and Drug Administration, Silver Spring, MD, USA. 4. Westat, Rockville, MD, USA. 5. Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA. 6. Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA. 7. Department of Health Behavior, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA.
Abstract
BACKGROUND AND AIMS: The US Family Smoking Prevention and Tobacco Control Act provides a pathway for manufacturers to market a modified risk tobacco product (MRTP). This study examines socio-demographic and tobacco use correlates of interest in a hypothetical MRTP in a nationally representative sample of US adults. DESIGN: Cross sectional wave 1 data from the 2013-14 Population Assessment of Tobacco and Health (PATH) Study. SETTING: Household Audio-Computer Assisted Self-Interviews of US adults conducted in 2013-14. PARTICIPANTS: A total of 32 320 civilian, non-institutionalized adults in the United States. MEASUREMENTS: Interest in using a hypothetical MRTP ('If a tobacco product made a claim that it was less harmful to health than other tobacco products, how likely would you be to use that product?'), socio-demographics, tobacco use history and mental health and substance use problems. All estimates were weighted. FINDINGS: Overall, 16.7% [95% confidence interval (CI) = 16.28, 17.18] of US adults reported interest in a hypothetical MRTP. Tobacco use was associated significantly with interest in a hypothetical MRTP, with interest most common among current established smokers (54.4%; 95% CI = 53.31, 55.39) and least common among never tobacco users (3.0%; 95% CI = 2.49, 3.55). Interest in a hypothetical MRTP was associated with experimental e-cigarette use among current experimental, current established and former smokers. Among non-smokers, race, age, education and substance use were associated with interest in using a hypothetical MRTP. CONCLUSIONS: Among adults in the United States, interest in using a hypothetical modified risk tobacco product is low overall, and highest among current experimental and established smokers. A small percentage of non-smokers are interested in using a hypothetical hypothetical modified risk tobacco product.
BACKGROUND AND AIMS: The US Family Smoking Prevention and Tobacco Control Act provides a pathway for manufacturers to market a modified risk tobacco product (MRTP). This study examines socio-demographic and tobacco use correlates of interest in a hypothetical MRTP in a nationally representative sample of US adults. DESIGN: Cross sectional wave 1 data from the 2013-14 Population Assessment of Tobacco and Health (PATH) Study. SETTING: Household Audio-Computer Assisted Self-Interviews of US adults conducted in 2013-14. PARTICIPANTS: A total of 32 320 civilian, non-institutionalized adults in the United States. MEASUREMENTS: Interest in using a hypothetical MRTP ('If a tobacco product made a claim that it was less harmful to health than other tobacco products, how likely would you be to use that product?'), socio-demographics, tobacco use history and mental health and substance use problems. All estimates were weighted. FINDINGS: Overall, 16.7% [95% confidence interval (CI) = 16.28, 17.18] of US adults reported interest in a hypothetical MRTP. Tobacco use was associated significantly with interest in a hypothetical MRTP, with interest most common among current established smokers (54.4%; 95% CI = 53.31, 55.39) and least common among never tobacco users (3.0%; 95% CI = 2.49, 3.55). Interest in a hypothetical MRTP was associated with experimental e-cigarette use among current experimental, current established and former smokers. Among non-smokers, race, age, education and substance use were associated with interest in using a hypothetical MRTP. CONCLUSIONS: Among adults in the United States, interest in using a hypothetical modified risk tobacco product is low overall, and highest among current experimental and established smokers. A small percentage of non-smokers are interested in using a hypothetical hypothetical modified risk tobacco product.
Keywords:
Epidemiology; Food and Drug Administration; Population Assessment of Tobacco and Health; modified risk tobacco products; public health; regulation; study; tobacco
Authors: J Hansson; N L Pedersen; M R Galanti; T Andersson; A Ahlbom; J Hallqvist; C Magnusson Journal: J Intern Med Date: 2009-06 Impact factor: 8.989
Authors: Stephen S Hecht; Steven G Carmella; Delshanee Kotandeniya; Makenzie E Pillsbury; Menglan Chen; Benjamin W S Ransom; Rachel Isaksson Vogel; Elizabeth Thompson; Sharon E Murphy; Dorothy K Hatsukami Journal: Nicotine Tob Res Date: 2014-10-21 Impact factor: 4.244
Authors: Israel T Agaku; Brian A King; Corinne G Husten; Rebecca Bunnell; Bridget K Ambrose; S Sean Hu; Enver Holder-Hayes; Hannah R Day Journal: MMWR Morb Mortal Wkly Rep Date: 2014-06-27 Impact factor: 17.586
Authors: Kira E Riehm; Andrea S Young; Kenneth A Feder; Noa Krawczyk; Kayla N Tormohlen; Lauren R Pacek; Ramin Mojtabai; Rosa M Crum Journal: Pediatrics Date: 2019-06-03 Impact factor: 7.124
Authors: Lilianna Phan; Andrew A Strasser; Andrea C Johnson; Andrea C Villanti; Raymond Niaura; Kathryn Rehberg; Darren Mays Journal: Tob Regul Sci Date: 2020-03
Authors: Kimberly G Wagoner; Beth A Reboussin; Jennifer Cornacchione Ross; Rachel Denlinger-Apte; John Spangler; Erin L Sutfin Journal: Addict Behav Date: 2022-05-07 Impact factor: 4.591
Authors: Darren Mays; Andrea C Johnson; Allison Glasser; Melissa Mercincavage; Andrew A Strasser Journal: Tob Control Date: 2021-10-29 Impact factor: 6.953
Authors: Diann E Gaalema; Irene Pericot-Valverde; Janice Y Bunn; Andrea C Villanti; Antonio Cepeda-Benito; Nathan J Doogan; Diana R Keith; Allison N Kurti; Alexa A Lopez; Tyler Nighbor; Maria A Parker; Amanda J Quisenberry; Ryan Redner; Megan E Roberts; Cassandra A Stanton; Philip A Ades; Stephen T Higgins Journal: Prev Med Date: 2018-05-08 Impact factor: 4.018
Authors: Sherine El-Toukhy; Sabeeh A Baig; Michelle Jeong; M Justin Byron; Kurt M Ribisl; Noel T Brewer Journal: Tob Control Date: 2018-08-29 Impact factor: 7.552
Authors: Olivia A Wackowski; Mariam Rashid; Kathryn L Greene; M Jane Lewis; Richard J O'Connor Journal: Int J Environ Res Public Health Date: 2020-09-18 Impact factor: 3.390